Abstract:Pilong Shi, 1, &ast Yuetong Sha, 1, &ast Xinran Wang, 1, &ast Tao Yang, 1 Jiawei Wu, 1 Jiajun Zhou, 1 Kai Liu, 1 Xue Guan, 2 Song Wang, 1 Yongsheng Liu, 1 Jingquan Gao, 3 Hongli Sun, 1 Tao Ban, 1 Yonggang Cao 1 1 Department of Pharmacology, Harbin Medical University, Heilongjiang, 163319, People's Republic of China; 2 Morphological Experiment Center, Harbin Medical University, Heilongjiang, 163319, People's Republic of China; 3 Department of Nursing, School of Medicine, Lishui University, Lishui, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yonggang Cao; Hongli Sun, Email ; Purpose: Myocardial ischemia-reperfusion injury (MI/RI) is associated with increased oxidative damage and mitochondrial dysfunction, resulting in an elevated risk of mortality. MI/RI may be alleviated by protecting cardiomyocytes from oxidative stress. Lutein, which belongs to a class of carotenoids, has proven to be effective in cardiovascular disease treatment due to its remarkable antioxidant properties, but its application is limited due to its poor stability and low bioavailability in vivo. Methods: In this study, a delivery system was developed based on distearoyl phosphatidyl ethanolamine (DSPE)-thiol-ketone (TK)-PEG2K (polyethylene glycol 2000) (abbreviated as DTP) and PCM-SH (CWLSEAGPVVTVRALRGTGSW) to deliver lutein (abbreviated as lutein@DTPP) to damaged myocardium. First, lutein, lutein@DTP, or lutein@DTPP were injected through the tail vein once a day for 3 days and then MI/RI model rats were established by exposing rats to ischemia for 45 min and reperfusion for 6 h. We employed a range of experimental techniques including qRT-PCR, Western blotting, transmission electron microscopy, immunohistochemistry, immunofluorescence, flow cytometry, immunoprecipitation, molecular docking, and molecular dynamics simulations. Results: Lutein@DTPP exhibited good myocardial targeting and ROS-responsive release. Our data suggested that lutein@DTPP effectively suppresses ferroptosis in cardiomyocytes. Mechanistically, we observed an upregulation of mouse double minute-2 (MDM2) in the hearts of MI/RI models and cardiomyocytes exposed to hypoxia/reoxygenation (H/R) conditions. In addition, NADH-ubiquinone oxidoreductase 75 kDa Fe-S protein 1 (NDUFS1) translocation from the cytosol to the mitochondria was inhibited by MDM2 upregulation. Notably, no significant variation in the total NDUFS1 expression was observed in H/R-exposed cardiomyocytes following treatment with siMDM2. Further study indicated that lutein facilitates the translocation of NDUFS1 from the cytosol to mitochondria by directly binding and sequestering MDM2, thereby improving mitochondrial function and inhibiting ferroptosis. Conclusion: Lutein@DTPP promoted the mitochondrial translocation of NDUFS1 to restore mitochondrial function and inhibited the ferroptosis of cardiomyocytes by directly binding and sequestering MDM2. Keywords: myocardial ischemia-reperfusion injury, lutein, ROS, MDM2, NDUFS1, ferroptosis Myocardial ischemia and its subsequent ischemia-reperfusion injury are significant contributors to myocardial injury and key pathophysiological processes in several cardiovascular diseases (CVDs), leading to increased healthcare costs and mortality rates. 1 Currently, therapeutic strategies for managing myocardial ischemia-reperfusion injury (MI/RI) primarily focus on protecting cardiomyocytes by removing reactive oxygen species (ROS), controlling inflammation, and limiting apoptosis. 2 Due to the substantial energy demands associated with contractile activity, the heart relies heavily on the preservation of normal mitochondrial respiration function. Emerging evidence indicates that mitochondrial dysfunction plays a crucial role in cardiomyocyte death and cardiac failure during energy-stress conditions, such as MI/RI. 3,4 Enhanced mitochondrial function ultimately enhances cell survival by aiding cardiomyocytes in coping with cellular ischemia stressors. 5 Thus, innovative cardioprotective strategies may be provided by novel therapeutics effective in mitigating mitochondrial dysfunction in MI/RI. 6,7 As the cell's power plant, mitochondria are responsible for generating adenosine triphosphate (ATP), the energy needed to support cellular life processes. 8 Under stress conditions, mitochondria regulate various biological activities, including signal transduction and metabolism. 9 The contraction and relaxation of the heart rely on a continuous supply -Abstract Truncated-

A Novel Danshensu-Tetramethylpyrazine Conjugate Dt-018 Provides Cardioprotection By Preserving Mitochondrial Function Through The Mef2d/Pgc-1 Alpha Pathway

A Novel Danshensu-Tetramethylpyrazine Conjugate DT-010 Provides Cardioprotection through the PGC-1α/Nrf2/HO-1 Pathway

Cardioprotection of a Novel Danshensu Derivate Against Oxidative Injury and Mitochondrial Dysfunction in Vitro and Myocardial Ischemia/Reperfusion Injury in Rat

A Novel Danshensu/tetramethypyrazine Derivative Attenuates Oxidative Stress-Induced Autophagy Injury Via the AMPK-mTOR-Ulk1 Signaling Pathway in Cardiomyocytes

[Mechanisms of Cardioprotection Induced by Preconditioning after Activation of MITOK(ATP) Channel].

Potent Protection Against MPP + -Induced Neurotoxicity Via Activating Transcription Factor MEF2D by a Novel Derivative of Naturally Occurring Danshensu/Tetramethylpyrazine

RTA 408 Ameliorates Diabetic Cardiomyopathy by Activating Nrf2 to Regulate Mitochondrial Fission and Fusion and Inhibiting NF-κB-mediated Inflammation.

A Novel Compound DT-010 Protects Against Doxorubicin-Induced Cardiotoxicity in Zebrafish and H9c2 Cells by Inhibiting Reactive Oxygen Species-Mediated Apoptotic and Autophagic Pathways

A novel Danshensu derivative confers cardioprotection via PI3K/Akt and Nrf2 pathways

Activated PKB/GSK-3β Synergizes with PKC-δ Signaling in Attenuating Myocardial Ischemia/reperfusion Injury Via Potentiation of NRF2 Activity: Therapeutic Efficacy of Dihydrotanshinone-I

Synthesis and Biological Evaluation of Danshensu and Tetramethylpyrazine Conjugates As Cardioprotective Agents

Inhibition of Mitochondrial Permeability Transition Pore: A Possible Mechanism for Cardioprotection Conferred by Pretreatment with Tanshinone IIA

Tetramethylpyrazine Attenuates Lipopolysaccharide-Induced Cardiomyocyte Injury Via Improving Mitochondrial Function Mediated by 14-3-3Γ.

Mechanistic Study on the Cardioprotective and Chemosensitizing Effects of a Novel Danshensu Derivative

Tingli Dazao Decoction pretreatment ameliorates mitochondrial damage induced by oxidative stress in cardiomyocytes

A Mitochondrion-Targeting Tanshinone IIA Derivative Attenuates Myocardial Hypoxia Reoxygenation Injury Through a SDH-dependent Antioxidant Mechanism

Cytoprotective Effects Evaluation of a Novel Danshensu Derivative DEX-018 Against Oxidative Stress Injury in HUVECs

The Novel Tetramethylpyrazine Bis-Nitrone (Tn-2) Protects Against Mptp/Mpp+-Induced Neurotoxicity Via Inhibition of Mitochondrial-Dependent Apoptosis

A Novel Agent Enhances the Chemotherapeutic Efficacy of Doxorubicin in MCF-7 Breast Cancer Cells.

Targeted Delivery and ROS-Responsive Release of Lutein Nanoassemblies Inhibit Myocardial Ischemia-Reperfusion Injury by Improving Mitochondrial Function

Dimethyl Fumarate Attenuates Lipopolysaccharide-Induced Mitochondrial Injury by Activating Nrf2 Pathway in Cardiomyocytes